Charles River Laboratories International (CRL) reported fiscal 2026 Q2 earnings on August 5, 2026, presenting a mixed financial picture that contrasts with broader market sentiment. While the company delivered a top-line revenue beat against consensus estimates, it simultaneously swung to a net loss, marking a significant deterioration from the prior year’s profitability.
Revenue
The total revenue of Charles River LaboratoriesCRL-- International decreased by 2.7% to $1 billion in 2026 Q2, down from $1.03 billion in 2025 Q2. This performance slightly exceeded consensus expectations by approximately $22.8 million. Within this total, the Discovery and Safety Assessment (DSA) segment remained the primary revenue driver, contributing $606.51 million. The Research Manufacturing Services (RMS) segment generated $209.47 million, while the Manufacturing segment contributed $188.10 million. Unallocated corporate costs were reported at $0, bringing the consolidated total revenue to exactly $1 billion.
Earnings/Net Income
Charles River Laboratories International swung to a loss of $0.03 per share in 2026 Q2 from a profit of $1.06 per share in 2025 Q2, representing a 102.8% negative change in earnings per share. Meanwhile, the company reported a net loss of $-760,000 in 2026 Q2, reflecting a 101.4% deterioration from the net income of $52.69 million achieved in 2025 Q2. Despite the GAAP loss driven by divestiture-related costs, the company reported a Non-GAAP EPS of $3.02, which beat consensus estimates by $0.29. This indicates that while operational profitability remains strong, significant one-time charges heavily impacted the bottom-line net income figure.
Price Action
The stock price of Charles River Laboratories International has edged down 2.71% during the latest trading day, has jumped 11.04% during the most recent full trading week, and has jumped 12.66% month-to-date.
Post-Earnings Price Action Review
For the most recent earnings window, the “buy CRLCRL-- after a revenue beat, hold 30 days” setup worked very well. From the latest earnings close on June 24, 2026 to the next 30th trading day close on August 5, 2026, CRL rose from $202.10 to $260.72, a +29.0% return.
This single-cycle backtest supports the idea that CRL can reward a momentum-follow-through trade after a revenue beat. The stock did not just gap and fade but continued to grind higher over the next month, which is the key quality for a 30-day trading strategy. If you want to run this as a real trade plan, treat it like this: setup quality matters because this worked due to strong follow-through, yet risk control still matters as a +29% winner does not mean the strategy is foolproof. The real test is whether revenue beats are repeatable and whether the stock keeps liquidity. Watch the revenue trend to see if CRL keeps beating quarter after quarter and monitor volatility after earnings, as excessive whippiness can still cause a 30-day hold to fail even on a good beat. Position sizing should be smaller than a diversified core holding because this is a single-stock momentum trade.
CEO Commentary
Birgit Girshick, Chief Executive Officer, highlighted strong execution of the "Pathway to Purpose" strategy, noting encouraging demand strengthening, particularly in the Discovery and Safety Assessment segment, evidenced by the highest net book-to-bill in nearly four years. She emphasized efforts to modernize operations, drive efficiency, and strengthen the regulated testing portfolio. Girshick expressed optimism about capturing additional share of client R&D spending through client-centric solutions and global scale. She affirmed that the company exceeded prior second-quarter financial targets, attributing this outperformance to improving demand trends and better-than-expected results in the Manufacturing segment, thereby validating the strategic focus on enhancing the growth profile and financial goals.
Guidance
The company raised its 2026 full-year revenue and non-GAAP earnings per share guidance, increasing organic revenue growth expectations by 150 basis points to a range of 0.0%–1.0% and raising the non-GAAP EPS midpoint by $0.25 to $11.15–$11.45. This upward revision primarily reflects operational outperformance driven by improving demand in the Discovery and Safety Assessment segment and stronger-than-expected results in the Manufacturing segment. Conversely, GAAP EPS guidance was reduced to $3.05–$3.35, principally due to net losses associated with the CDMO and Cell Solutions divestitures. Management noted that second-quarter deferred compensation investment gains are expected to be largely offset by a higher tax rate in the full year, resulting in a negligible net impact on non-GAAP EPS.
Additional News
Institutional ownership of Charles River Laboratories remains robust, with Bank of America Corp DE increasing its stake by 5% in the first quarter. The financial giant acquired 54,500 additional shares, bringing its total holdings to 1.14 million shares valued at approximately $195.8 million. This move underscores continued confidence in the CRO giant’s long-term trajectory despite recent market volatility. Conversely, insider activity showed Director James C. Foster selling 75,000 shares for $16.9 million under a pre-arranged Rule 10b5-1 trading plan, a standard automated selling mechanism that does not necessarily reflect a lack of faith in the company. Analyst sentiment remains cautiously optimistic, with a consensus “Moderate Buy” rating and an average price target of $220.75. The stock recently traded within a 52-week range of $144.26 to $242.73, indicating significant recovery potential from lower lows.
